Date: Jan 19, 2010 Source: Company Data (
click here to go to the source)
Michael J. Fox Foundation Awards Research Grant to EnVivo as Part of Initiative Seeking New Parkinson's Disease Treatments
01/19/2010
WATERTOWN, Mass., January 19, 2010 -- EnVivo Pharmaceuticals, Inc. has been awarded a research grant by the Michael J. Fox Foundation for Parkinson's Research (MJFF). The grant will fund research as part of the foundation's Therapeutics Development Initiative that seeks new treatments for Parkinson's disease. Read the entire MJFF press release here.
Under this 19-month grant, EnVivo will test its Histone Deacetylase inhibitor (HDACi) EVP-0334 in two different mouse models of Parkinson's disease to demonstrate that EVP-0334 can potentially slow the progression of Parkinson's disease. EVP-0334 is currently being clinically developed by EnVivo for the treatment of Alzheimer's disease.
HDACs are a family of enzymes that epigenetically regulate gene expression and can affect protein clearance. Inhibitors of HDACs have previously been reported to be efficacious in cellular and animal models of Parkinson's disease.
